Background: Macrolide antibiotics may cause QT prolongation.
Introduction
Bacterial resistance to antimicrobial agents and the growing number of pathogenic organisms that are resistant to multiple drugs are of increasing concern to medical and public health communities worldwide. In recent years, rapid emergence of macrolide resistance has begun to limit therapeutic options for the treatment of respiratory infections, resulting in the need for newer agents that are active against resistant strains. Macrolides were introduced into antibacterial therapeutics, beginning with erythromycin A, in the early 1950s. Erythromycin and the newer macrolides, including clarithromycin and azithromycin, continue to be mainstay treatments for respiratory infections.
Solithromycin, a fourth-generation macrolide and the first fluoroketolide, has been developed as oral, intravenous (iv) and paediatric suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP) . Solithromycin has demonstrated potent in vitro activity against key respiratory pathogens including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis as well as atypical pathogens (Legionella pneumophila and Mycoplasma pneumoniae). In two large Phase 3 trials enrolling a total of 1723 patients, solithromycin was non-inferior to moxifloxacin for the treatment of CABP. 1, 2 Solithromycin is also being evaluated for treatment of adult patients with urogenital gonorrhoea and paediatric patients with CABP. Due to its potent anti-inflammatory properties, 3, 4 it is also being evaluated in proofof-concept studies in non-alcoholic steatohepatitis and COPD. Due to its extended spectrum of activity and pharmacological properties, solithromycin could also be evaluated for other indications, such as bacterial urethritis, tuberculosis, malaria and biodefence.
Certain non-antiarrhythmic compounds have been shown to cause QT prolongation, which in rare cases can lead to a potentially lethal polymorphic ventricular tachycardia known as torsades de pointes (TdP). 5 -8 All new chemical entities with systemic exposure are therefore required to undergo a so-called thorough QT (TQT) study as described in the International Council for Harmonization (ICH) E14 clinical guidance document, which was issued in May 2005. 9, 10 Antibiotics including respiratory fluoroquinolones such as moxifloxacin and levofloxacin and also older macrolides such as erythromycin, clarithromycin and azithromycin are known to cause QT prolongation. 11 -13 Solithromycin is a new-generation macrolide and a key safety concern to address as part of the clinical development was therefore a careful characterization of ECG effects. This paper describes the results and clinical interpretation of a TQT study, which has shown that solithromycin, unlike other macrolides, does not cause QT prolongation.
Patients and methods
This was a Phase 1, single-centre, three-way crossover, placebo-and active-controlled, double-blind, randomized trial. A total of 48 subjects were to be randomly assigned to receive single doses of solithromycin, moxifloxacin and placebo in separate periods. Each period had a duration of 2 days and there was a washout of 5 days between periods. Treatments were administered in the morning after an overnight fast and subjects remained fasted for 4 h post-dosing. Subjects were randomly assigned to one of the following six different treatment sequences: ABC, ACB, BAC, BCA, CAB and CBA with the following treatments: (A) 800 mg of solithromycin as an iv infusion over 40 min; (B) placebo for solithromycin (0.9% sodium chloride) as an iv infusion over 40 min; and (C) 400 mg of oral moxifloxacin as an open-label tablet plus placebo for solithromycin as an iv infusion over 40 min.
During each of the three study periods, subjects were confined in a Phase 1 unit from the afternoon on the day before dosing until safety evaluations had been completed on day 2. On day 1, subjects received a single dose of study drug, after which ECGs, vital signs and blood samples for pharmacokinetics (PK) determination were serially collected. Healthy subjects aged 18 -55 years, inclusive, with absence of clinically significant abnormalities on 12 lead ECG were enrolled. The study was conducted from October 2013 to January 2014 at SNBL Clinical Pharmacology Center, Baltimore, MD, USA.
Ethics
The study was conducted in accordance with good clinical practice, including ICH guidelines, and in general conformity with the most recent version of the Declaration of Helsinki. All subjects gave their written, informed consent and the study was approved by IntegReview IRB, Austin, TX, USA (reference: Protocol CE01-109; approval date: 26 September 2013).
ECG assessment
Continuous 12 lead ECG recordings were performed using a Global Instrumentation (Manlius, NY, USA) M12R ECG digital recorder. Up to 10 non-overlapping ECG replicates were extracted by the central ECG laboratory (iCardiac Technologies, Rochester, NY, USA) at the following timepoints: 30, 20 and 10 min before the start of infusion and at 40 min (immediately prior to end of infusion) and 1, 2, 3, 4, 6, 8, 12 and 24 h after the start of infusion. Subjects were supinely resting in an undisturbed environment for ≥10 min prior to and 5 min after each timepoint for ECG extraction. ECG intervals were measured with the high-precision QT technique. 14 The measured QT data were heart rate (HR) corrected using QTcF and individual correction methods (QTcI). For each subject, all QT/RR pairs from a full 24 h ECG recording on the day before dosing in period 1 were used to derive that subject's individual correction formula; based on the QT/RR pairs from the subject, the QTcI correction factor was derived from linear regression modelling: log(QT)¼log(a)+b×log(RR). The coefficient of log(RR), b, was then used to calculate the optimized QTcI for that subject as follows: QTcI¼QT/RR b .
Statistical methods
For all ECG parameters, the mean of the measurements obtained at the three pre-dose timepoints of each treatment period were used as the baseline for each post-dose timepoint in the same treatment period. 15 The correction method that resulted in the average on-treatment slope closest to zero (the smallest average SSS) was deemed the most appropriate HR correction method and was therefore used as the primary endpoint.
The analysis was the difference between change-from-baseline QTc (DQTc) for solithromycin and placebo. The primary evaluation was based on a linear mixed-effects model with DQTc as the dependent variable, time (categorical), treatment (solithromycin, moxifloxacin and placebo) and time-by-treatment interaction as factors and baseline QTc as covariate. Since this was a crossover design, period and sequence terms were also included in the model. Subject was included as a random effect for the intercept. A compound symmetry covariance structure was specified for the repeated measures at post-dose timepoints for subject within period. For this analysis, a 90% two-sided CI was calculated for the contrasts 'solithromycin 2placebo'.
The analysis to show assay sensitivity was based on the DQTc of moxifloxacin, whereby the same model was used as described for the primary analysis. For the timepoints 2, 3 and 4 h, the contrast in treatment DDQTc ¼ 'moxifloxacin 2 placebo' was tested against the one-sided null hypothesis DDQTc ≤5 ms on the 5% level. Multiplicity was controlled by using a Hochberg procedure. 16 If after this procedure the DDQTc was significantly .5 ms for at least one timepoint, assay sensitivity was considered shown. For other ECG parameters (i.e. HR, PR, QRS and QTc not chosen as primary endpoint), descriptive analysis for change-frombaseline and placebo-corrected change-from-baseline values were listed in the tables and graphically displayed.
The relationship between DDQTcF and solithromycin plasma concentrations was investigated by a linear mixed-effects modelling approach, which included all available pairs of solithromycin concentration/QTc data from all subjects and post-dosing timepoints:
where DDQTcF ij was the time-matched, placebo-corrected change-frombaseline QTcF for subject i at time j with concentration Conc ij . The residual 1 ij was assumed to be identical, independent, normally distributed (iidN) with mean 0 and variance s 2 . Three linear models were considered: (i) a model with an intercept [i.e. Intercept i was assumed to be iidN(A, s included in the model as a covariate and subject as a random effect for both intercept and slope, whenever applicable. A final assessment of the adequacy of the linear mixed-effects model was provided by a goodness-of-fit plot (i.e. the observed concentration decile -DDQTcF plot) as proposed by the FDA's Interdisciplinary Review Team. 15 The model that best fitted the data (i.e. had the smallest Akaike information correction and predicted CIs similar to the observed CIs) was used for predicting DDQTcF at the geometric mean peak solithromycin.
The above analysis was repeated for DDHR with the log transformation of solithromycin plasma concentration values as covariate since the linear mixed-effects models with solithromycin plasma concentration values in their original scale did not fit the HR data.
PK determination
Plasma samples were collected serially on day 1 before the start of infusion and then at the same timepoints as for ECG extraction. ECG extractions were time-matched to the PK samples. Blood samples (3 mL each) were drawn into tubes containing dipotassium EDTA (K 2 EDTA), inverted several times to mix the blood with the anticoagulant and placed in an ice bath. Within 30 min of collection, the samples were centrifuged for 10 min at 3000 rpm at 58C. The plasma was separated using a disposable plastic pipette and approximately half of the plasma was transferred into duplicate cryotube vials and frozen at 2808C (+158C) until shipment. Moxifloxacin samples were stored and were to be analysed only if demonstration of assay sensitivity was not successful. 17 Plasma concentrations of solithromycin were assayed using a validated LC-MS/MS method by Tandem Labs (Durham, NC, USA) with a quantification range of 10.0 -10000 ng/mL. The robustness of the assay was confirmed by performance of solithromycin quality control samples during sample bioanalysis, which demonstrated a precision (% coefficient of variation) that ranged from 2.5% to 2.9% and an accuracy (% bias) that ranged from 21.3% to 0.8%.
Results
Forty-eight subjects were enrolled in the study and all 48 subjects received at least one of the three treatments ( Figure 1 ). ECG parameters were well balanced across the pre-dose baseline before each treatment, with a mean difference in HR ,2 bpm, a mean difference for QTcF and QTcI ,1 ms and negligible differences in mean PR and QRS intervals.
PK
After the 40 min infusion of 800 mg of solithromycin, a mean C max of 5.9 (SD: 1.30) mg/mL was observed at the end of the infusion; plasma levels thereafter declined quickly with a mean level of 2.7 (0.70) mg/mL 20 min later (1.0 h timepoint). This initial rapid decline was followed by a more gradual decrease in plasma levels over the next 23 h that suggested first-order kinetics with mean plasma levels at the last quantifiable timepoint (24 h postinfusion initiation) of 0.2 (0.10) mg/mL (Figure 2 ). Moxifloxacin PK samples were not analysed, since assay sensitivity was demonstrated by the QT response, as described below.
Electrocardiographic effects
The solithromycin infusion caused an increase in HR (Figure 3a) . Immediately after the end of the infusion (0.67 h), the placebocorrected, change-from-baseline HR (DDHR) peaked at 15 bpm and thereafter remained elevated for 12 h post-dosing, with values .12 bpm for 8 h (Table 1) . When the HR effect was evaluated using exposure -response analysis, a linear model with an intercept best fitted the data. An effect of solithromycin plasma concentrations on the HR was identified with a statistically significant slope of the relationship of 3.0 bpm per log ng/mL (90% CI: 2.42 -3.59; P, 0.0001). The HR effect seemed to level off in the two highest concentration deciles, which may suggest that this effect reaches a plateau in healthy subjects.
The slope estimate for QTcI calculated from QT/RR pairs during the placebo treatment period was somewhat lower than for QTcF (0.300). Both QTcF and QTcI corrected well for HR Randomized and dosed n = 48
Solithromycin n = 47
Placebo n = 44
Moxifloxacin n = 45 Figure 1 . Study flow chart. Forty-eight subjects were randomized and received at least one of the three treatments; 43 subjects received all three treatments and completed the study. Forty-seven subjects received solithromycin, 44 received placebo and 45 received moxifloxacin. There were three protocol violations during the study, all of which were based on positive alcohol/drug screens. . Solithromycin plasma concentrations (mean+SE) after a 40 min infusion of 800 mg. Peak plasma levels were observed immediately after the end of the infusion, with an initial rapid decline, followed by a slower elimination phase. C max peaked at 5.9+1.30 mg/mL (mean+SD). Plasma concentrations that were below the quantification limit (BQL) were treated as zero for timepoints prior to the first and after the last quantifiable concentration. The BQL values that occurred between any post-dose timepoints were treated as missing.
TQT study with solithromycin JAC changes with comparable mean SSS on solithromycin (0.0009 for QTcF and 0.0010 for optimized QTcI). Based on a lower mean SSS on all treatments, QTcF was chosen as the primary endpoint. Change-from-baseline QTcF (DQTcF) was similar after dosing with 800 mg of iv solithromycin and placebo and followed the same diurnal pattern, whereas DQTcF on moxifloxacin showed clear prolongation (Figure 3b ). The resulting placebo-corrected DQTcF (DDQTcF) on solithromycin was therefore small at all postdosing timepoints (Table 1 ) with the largest DDQTcF of 2.8 ms with the upper bound of the 90% CI of 4.9 ms observed at 4 h. The QT prolongation observed after an oral dose of 400 mg of moxifloxacin confirmed the study's ability to demonstrate a small QT effect. Mean DDQTcF was 9.7, 9.8 and 10.9 ms at the three pre-defined timepoints (2, 3 and 4 h post-dosing) with the lower bound of the 90% CI .5 ms (7.6, 7.7 and 8.7 ms, respectively; Table 1 ), thereby meeting the requirements for assay sensitivity. 9 There were no subjects with a QTcF value .450 ms or DQTcF .30 ms at any post-dosing timepoint. Results for QTcI were consistent with results for QTcF (data not shown).
A scatter plot of all observed pairs of solithromycin plasma levels and DDQTcF for all post-dosing timepoints and subjects is shown in Figure 4 (a). In the exposure-response analysis, a linear model with an intercept provided the best fit to the data. An assessment of the adequacy of the linear mixed-effects model is given by the goodness-of-fit plot in Figure 4 (b), which shows the mean DDQTcF (90% CI) within each solithromycin plasma concentration decile and the model-predicted mean DDQTcF with 90% CI. A shallow, statistically significant negative slope was observed for the relationship between solithromycin plasma levels and DDQTcF with a mean slope of 20.86 ms per mg/mL (90% CI: 21.19 to 20.53; P ¼ 0.0001). Darpo et al.
Solithromycin did not have a clinically meaningful effect on the PR or QRS interval. Mean placebo-corrected DPR was ≤2.0 ms during the first 8 h after the infusion and mean placebo-corrected DQRS within +0.5 ms at all post-dosing timepoints.
Safety
The most frequently reported treatment-emergent adverse event was infusion site pain of mild or moderate severity and was reported by 28 (59.6%) subjects following administration of solithromycin. All other adverse events were reported by two or fewer subjects without clear relationship to any treatment. No subject reported an adverse event that could be associated with the observed HR effect, e.g. tachycardia or palpitations. There were no serious adverse events or clinically significant laboratory findings. Three subjects experienced an ALT level greater than the upper limit of normal in follow-up (two after solithromycin and one after moxifloxacin), none of which was .2× baseline value.
Discussion
In this TQT study, a 40 min infusion of 800 mg of solithromycin resulting in a mean C max of 5.9 mg/mL did not cause an effect on cardiac repolarization, as measured by QTcF or QTcI. The placebo-corrected DQTcF (DDQTcF) was small at all timepoints for solithromycin and an effect .10 ms could be confidently excluded at the highest achieved plasma concentration levels. The study thereby constitutes a clearly negative TQT study as defined by the ICH E14 guidance. 9, 10 Exposure-response analysis of the data confirmed the lack of a clinically relevant effect with a shallow and slightly negative relationship between solithromycin plasma concentrations and DDQTcF (20.86 ms per mg/mL; 90% CI: 21.19 to 20.53). Based on these data, it can be concluded that within the observed range of plasma concentrations in this study, up to 8 mg/mL, solithromycin will not cause QT prolongation.
The target of the 800 mg iv solithromycin dose in this study was to achieve supratherapeutic plasma levels as compared with those observed in patients. This was achieved by infusing a high dose as rapidly as solubility permitted, i.e. 800 mg in 500 mL of 0.9% sodium chloride infused over 40 min, as compared with 400 mg infused over 60 min in patients. Among CABP patients in Phase 3 studies, the mean C max with iv dosing of 400 mg over 60 min was 3.1 mg/mL and with transition to oral dosing (first dose, 800 mg) the mean C max was 2.2 mg/mL. With oral dosing alone, the mean C max of the initial 800 mg dose was 1.5 mg/mL. Solithromycin is both a CYP3A4 substrate and inhibitor. As a result, coadministration of solithromycin with another CYP3A4 inhibitor is expected to increase first-dose exposure, but to have minimal additional effect at steady-state as solithromycin inhibits its own metabolism. In an oral solithromycin/ ketoconazole drug -drug interaction study, the solithromycin C max following a 400 mg dose increased 1.6-fold. The same effect on C max is not expected to be seen with iv dosing. In patients with hepatic impairment, the mean solithromycin C max after 5 days of oral dosing of 800 mg first dose/400 mg subsequent doses was only 1.2-fold higher in any of the Child -Pugh classes (A, B and C) as compared with healthy subjects. A larger increase in C max levels can, however, be expected in patients with severe renal impairment, in whom 1.8-fold higher levels have been observed as compared with healthy subjects. Accordingly, a reduced dose will be recommended for patients with severe renal impairment. Based on these observations, it can be concluded that plasma concentrations achieved in this TQT study clearly exceeded those in patients, including expected C max levels in patients with TQT study with solithromycin JAC impaired clearance of the drug. In this context, it is also important to note that exposure-response analysis of data from this study allows for the prediction of QT effect within the observed range of plasma concentrations, i.e. up to 8 mg/mL, substantially above those observed in patients. As shown by this analysis, a slight shortening of the QTc interval can be estimated at these very high plasma concentrations. Since the study's ability to detect a small QTeffect was confirmed by the response to the positive control, moxifloxacin, it is reassuring that the predicted effect at these high solithromycin concentrations is well below the threshold of concern, i.e. 10 ms. Solithromycin given iv at this dose (800 mg over 40 min) to healthy subjects had an unambiguous effect on the HR with an increase of 15 bpm immediately after the infusion and declining thereafter. There were no signs of vasodilation with a reduction of blood pressure during the infusion, thus the HR effect does not represent reflex tachycardia. The observed HR effect in healthy subjects exposed to high plasma concentrations of solithromycin raises the important question of whether this may translate into an adverse clinical effect in patients with an infection, who are febrile and under stress and in whom tachycardia is often observed when treatment is initiated. In a recent Phase 3 CABP trial in which solithromycin was administered orally once daily at 800 mg on the first day, followed by 400 mg for 4 days, 1 the mean daily HR in patients receiving solithromycin decreased following dosing, suggesting a different response in these patients as compared with healthy subjects. The HR declined in the solithromycin group by a mean of 9, 8 and 13 bpm after 2, 4 and 5 days of therapy, as compared with 13.9, 14.1 and 20 bpm in patients in the comparator group treated with moxifloxacin. It could be argued that the decline is more pronounced on moxifloxacin than on solithromycin, but in a more controlled setting, this difference was not observed. In a second Phase 3 CABP trial evaluating iv to oral solithromycin for 7 days (400 mg iv over 60 min up to 7 days, with an option to switch to 800 mg orally followed by 400 mg orally) in hospitalized patients, a more robust collection of HR data was performed.
2 At 4 h post-dose on the first day of treatment, the mean HR was lowered by 5.5 bpm in solithromycin patients and by 5.7 bpm in patients receiving moxifloxacin and no large differences were observed on subsequent days. We believe that these data illustrate that the HR effect is dramatically different when infected patients are treated with an effective antibiotic as compared with healthy subjects and therefore likely to be of little clinical relevance.
There were no serious cardiac adverse events considered related to solithromycin treatment observed in either the Phase 3 study or in a Phase 2 study with the same oral dosing regimen; 18 therefore, there is no suggestion that the HR effect observed in healthy subjects would adversely impact the cardiac safety of patients with an infection.
Earlier-generation macrolides have been associated with QT prolongation and TdP proarrhythmias in susceptible patients. Erythromycin, clarithromycin, azithromycin and roxithromycin are listed on the CredibleMeds web site as drugs with known risk of TdP, whereas telithromycin is listed as a drug with possible TdP risk. 12 Within the limitations of observational studies with potential selection bias, it can also be noted that certain macrolides have also been associated with an increased risk of sudden cardiac death and ventricular arrhythmias. 19, 20 It is therefore comforting to learn that QT prolongation is not a class effect of macrolides in general and that solithromycin, when studied under the rigorous conditions of a TQT study, is devoid of this adverse effect. This allows for the potential wider use of solithromycin in patients at risk of proarrhythmias, e.g. patients with cardiovascular disease, patients with electrolyte disturbances and patients on other drugs, which are not CYP3A4 substrates, with potential QT effects.
Funding
The study was supported by Cempra Inc. 
Transparency declarations

